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Abstract
Öz
Amaç: Hipertansiyon artmış trombosit fonksiyonu ile ilişkilidir. Bazı antihipertansif 
ilaçların anti-trombosit aktiviteleri vardır. Biz bu çalışmada, losartanın adenozin difosfat 
(ADP), kollajen, epinefrin, ristosetin ile trombosit agregasyonuna, diğer hematolojik ve 
enflamatuvar parametreler üzerine etkilerinin araştırılmasını amaçladık.
Objective: Hypertension is associated with increased platelet function. Some 
antihypertensive drugs have antiplatelet activity. In this study, we aimed to 
investigate the effects of losartan on platelet aggregation induced by adenosine 
diphosphate (ADP), collagen, epinephrine, ristocetin, other hematological and, 
inflammatory parameters. 
Materials and Methods: Twenty-five patients (19 female, 6 male; mean age: 54±8 
years) with newly diagnosed hypertension were included in the study. All patients 
were with stage 1-2 essential hypertension according to the seventh report of 
the Joint National Committee on prevention, detection, evaluation, and treatment 
of high blood pressure. Initial blood pressure measurement was performed in 
all patients and losartan 100 mg/daily together with life style changes, such as 
diet and exercise was started. Platelet aggregation was evaluated with the use of 
ristocetin, epinephrine, collagen, and ADP. Complete blood count was also done. 
Platelet aggregation tests and blood pressure measurements were repeated after 8 
weeks of therapy. 
Results: Systolic and diastolic blood pressure significantly decreased with losartan 
after 8 weeks (p<0.001). After treatment, there was no significant difference in 
platelet aggregation with ADP, collagen, and epinephrine (p>0.05). The aggregation 
with ristocetin significantly decreased (p=0.027). Besides, significantly lower 
hemoglobin and hematocrit levels were observed (p=0.034, p=0.039, respectively).
Conclusion: Losartan may produce independent activities apart from its 
antihypertensive effects by providing significant reductions in platelet aggregation 
with ristocetin, and in hematocrit levels with hemoglobin. Therefore, it may be 
beneficial in the prevention of atherosclerosis and thrombosis. 
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Introduction
Hypertension is a multifactorial and 
heterogeneous disease that presents as high blood 
pressure. Uncontrolled hypertension can cause 
stroke, myocardial infarction, heart failure, chronic 
kidney disease, and premature death (1). Angiotensin 
receptor blockers (ARBs) are effective and safe drugs. 
Angiotensin II is the main active component of the 
renin-angiotensin system. In addition, angiotensin II 
is an etiological factor for hypertension. Angiotensin 
II type-1 (AT1) receptor stimulation has been shown 
to be associated with effect of angiotensin II (2,3). 
Losartan is one of the orally active non-peptidic AT1 
receptor antagonists (2).
ARBs are used for the treatment of heart failure and 
nephropathy. Besides, ARBs prevent new or recurrent 
stroke incidence in hypertensive patients. In addition, 
ARBs have been shown to possess antiatherogenic, 
antioxidant, antidiabetic, and antiplatelet aggregating 
effects. These beneficial effects show that ARBs have 
pleiotropic effects (3). In several studies, it has been 
shown that essential hypertension was associated 
with increased platelet aggregation (4). Some classes 
of antihypertensive drugs have also antiplatelet 
activity (5-7).
In this study, our aim was to investigate the effects 
of losartan on in-vitro induced platelet aggregation by 
adenosine diphosphate (ADP), collagen, epinephrine, 
ristocetin, erythrocyte sedimentation rate (ESR), and 
C-reactive protein (CRP) levels as well as platelet and 
white blood cell (WBC) counts.
Materials and Methods 
This study included 25 patients (19 female, 6 male; 
mean age: 54±8 years) with essential hypertension. All 
patients were with stage 1-2 essential hypertension 
according to the seventh report of the Joint National 
Committee on the prevention, detection, evaluation, 
and treatment of high blood pressure (8). Blood 
pressure measurements were performed after the 
subjects had rested in the supine position for at least 15 
minutes in a quiet examining room, at the same room 
temperature, with the same sphygmomanometer. 
Three measurements were done at 2-minute intervals 
and the mean value was recorded. Exclusion criteria 
were: coronary artery disease, heart failure, secondary 
hypertension, an acute illness, obesity (body mass 
index >35 kg/m2), a previous diagnosis of thrombotic 
events, known hypercoagulable states, major surgery 
in the past 3 months, current exposure to anti-platelet 
therapy, non-steroidal anti-inflammatory drugs use, 
anti-hyperlipidemic therapy, antidepressant drugs or 
oral contraceptives use, smoking, diabetes mellitus, 
chronic renal failure, malignancy, and history of 
allergic reaction to losartan. 
All patients underwent physical examination. 
Urinalysis, and laboratory tests (blood counts, renal 
function tests, electrolytes, lipid levels, CRP, ESR) 
were evaluated. After stopping drugs for 10 days, 
platelet aggregation tests with ADP, epinephrine, 
collagen, and ristocetin were performed. All patients 
underwent chest X-ray and 12-lead electrocardiogram. 
Biochemical analyses and CRP measurements were 
performed using an immuno-analyzer (Access 
Immunoassay System, Beckman-Coulter). Losartan, 
100 mg/daily together with life style changes, such 
as diet and exercise were started. The patients were 
asked to take their medication at 10:00 am. Platelet 
aggregation tests and blood pressure measurements 
were repeated 8 weeks after therapy. Informed 
consent was obtained from all participants. 
Platelet aggregation (Chrono-log, 570 blood 
aggregation systems, Havertown, USA) was evaluated 
Gereç ve Yöntem: Çalışmaya yeni tanı hipertansiyonlu ortalama yaşı 54±8 yıl olan 19’u kadın, 6’sı erkek 25 hasta alındı. Yüksek 
kan basıncını önleme, saptama, değerlendirme ve tedavi üzerine Birleşik Komite’nin yedinci raporuna göre tüm hastaların, evre 1-2 
esansiyel hipertansiyon tanısı mevcuttu. Başlangıç kan basınçları ölçüldü ve her bir hastaya diyet, egzersiz gibi yaşam tarzı değişikliği 
ile birlikte losartan 100 mg/gün tedavisi başlandı. Tedavi öncesi ristosetin, epinefrin, kollagen ve ADP ile trombosit agregasyonu 
değerlendirildi. Ayrıca tam kan sayımları ölçüldü. Trombosit agregasyon testleri ve kan basıncı ölçümleri tedaviden 8 hafta sonra 
tekrar değerlendirildi.
Bulgular: Losartan ile 8 haftanın sonunda sistolik ve diyastolik kan basıncında anlamlı düşüş saptandı (p<0,001). Tedavi sonrası, ADP, 
kollajen ve epinefrin seviyeleri ile trombosit agregasyonunda anlamlı farklılık saptanmadı (p>0,05). Ristosetin ile agregasyon önemli 
ölçüde azaldı (p=0,027). Aynı zamanda, önemli ölçüde düşük hemoglobin ve hematokrit seviyeleri gözlemlendi (p=0,034 ve 0,039, 
sırasıyla).
Sonuç: Losartan, hemoglobin ile hematokrit seviyelerinde ve ristosetinle trombosit agregasyonunda önemli ölçüde düşüş sağlayarak 
antihipertansif etkisinden bağımsız aktiviteler ortaya koyabilir. Bu sayede aterosklerozun ve trombozun önlenmesinde faydalı olabilir.
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with the use of ristocetin, epinephrine, collagen, and 
ADP. Complete blood count (Beckman-Coulter) was 
also evaluated.
Twenty milliliter venous blood samples were 
anticoagulated with 1 ml of 3.8% trisodium citrate. 
Aggregation test was performed within 30 minutes 
after sampling. Platelet-rich plasma (PRP) was 
prepared by centrifugation of the blood at 800 rpm 
for 15 minutes at 20 °C. For each test, 450 μL PRP 
were collected in glass tubes and were fitted up in PRP 
washbowl. The supernatant was drawn into another 
tube, and the remaining PRP again centrifuged at 4000 
rpm for 10 minutes to obtain platelet-poor plasma 
(PPP). Four hundred-fifty μL PPP was put into PPP 
washbowl and incubated at 37 °C for 2 minutes. Then 
it was stirred again for 2 minutes in the aggregometer. 
Changes in optical density were recorded for 6 
minutes after the platelets were stimulated with 
ADP, epinephrine, collagen and ristocetin. ADP, 
epinephrine, and collagen were studied by 3 μL and 
ristocetin was studied by 4 μL. A turbidity curve 
expressing the relationship between the amplitude 
and the rate of the aggregation was calculated for 
each patient’s sample. The lowest light transmission 
at the end of the 6 minutes was recorded as the 
maximal aggregation percentage (%). The time that 
50% of maximal aggregation occurred was recorded 
as the aggregation rate (seconds) (9,10). 
Statistical Analysis
Statistical Package for Social Sciences version 16.0 
was used for statistical analyses. A p value of less 
than 0.05 was considered statistically significant. All 
results were presented as mean ± standard deviation. 
Fit of the quantitative data to normal distribution was 
studied using the Kolmogorov Smirnov test. Statistical 
analyses were performed using two-paired student’s 
t-test. 
Results 
Parameters before and after treatment with 
losartan are shown in Table 1. Systolic and diastolic 
blood pressure significantly decreased with losartan 
after 8 weeks of treatment (p<0.001). After treatment, 
there was no significant difference in platelet 
aggregation with ADP, collagen, and epinephrine 
(p>0.05). After losartan treatment, platelet 
aggregation with ristocetin significantly decreased 
(p=0.027). In addition, hemoglobin and hematocrit 
levels decreased significantly (p=0.034, p=0.039, 
respectively). However, there was no difference in 
ESR, CRP levels, platelet counts, and WBC counts 
(p>0.05). 
Discussion
In our study, we detected a significant decrease 
in hematocrit levels with hemoglobin and platelet 
aggregation with ristocetin in patients treated with 
losartan. 
Atherosclerosis develops as a process occurring 
in the walls of arteries, which begins with a cellular 
and infiltrative response to an endothelial injury (11). 
Circulating activated platelets have been shown to 
be associated with an increased risk of thrombotic 
events. This condition is related to stroke, diabetes 
mellitus, and hyperlipidemia (12). 
Activated platelets play an important role in the 
formation of acute coronary syndromes including 
platelets and endothelial cells, leukocytes, and 
erythrocytes. Angiotensin II as a vasoconstrictor could 
contribute to thrombotic process. Platelets express 
AT1 receptors on their surface (13,14). Losartan is 
one of the non-peptidic AT1 receptor antagonists. In 
Ünübol et al. The Effect of Losartan on Platelet Aggregation
Table 1. Parameters before and after treatment with 
losartan
Before 
treatment
After 
treatment
p*
Systolic blood 
pressure (mmHg)
161±15 122±9 <0.001
Diastolic blood 
pressure (mmHg)
96±8 80±2 <0.001
Ristocetin (%) 78±18 64±22 0.027
ADP (%) 82±18 79±14 >0.05
Collagen (%) 93±14 92±14 >0.05
Epinephrine (%) 70±21 64±20 >0.05
Hemoglobin (g/dL) 13.9±1.5 13.3±1.2 0.034
Hematocrit (%) 39.8±4.3 38.5±3.3 0.039
White blood cell 
counts (µl) x103
6.7±1.3 6.4±1.5 >0.05
Platelet counts (µl) 
x103
271.4±45.9 267.6±70.4 >0.05
ESR (mm/h) 23±13 24.6±12 >0.05
CRP (mg/L) 1.6±2.9 1.8±2.3 >0.05
ADP: Adenosine diphosphate, ESR: Erythrocyte sedimentation rate, 
CRP: C-reactive protein, * Two-paired student’s t-test was used
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their study, Montón et al. (13) stimulated platelets 
with the thromboxane A2 (TxA2) analogue U46619. 
They have found that stimulated platelet activation 
by the TxA2 analogue U46619 was significantly 
reduced by losartan. Jimenez et al. (15) demonstrated 
that losartan decreased P-selectin expression in 
platelets obtained from stroke-prone spontaneously 
hypertensive rats. On the other hand, administration 
of losartan decreased the number of activated 
platelets independently of its antihypertensive effects.
In Japanese patients with mild-to-moderate 
hypertension (J-ELAN) study (16) losartan and 
amlodipine were compared and losartan was found 
to be efficient in preventing the progression of 
atherosclerosis of the carotid artery.
In a study by Chabielska et al., (17) acute and 
sub chronic (5 days) losartan administration did not 
change the aggregating response of normotensive 
rat platelets. Nossaman et al. (18) demonstrated that 
losartan significantly decreased arachidonic acid-
induced platelet aggregation in a rat, but candesartan 
had no effect.
Sato et al. (2) showed the inhibition of platelet 
aggregation with ADP after losartan treatment. They 
used highly sensitive particle counting method using 
laser-light scattering. They stated that this effect 
could be independent of antihypertensive actions 
and the positive effects of losartan on decreasing 
cardiovascular events in hypertensive patients might 
be partly mediated by inhibition of platelet activation. 
Nomura et al. (19) found that CD62P, CD63, PAC-1 (a 
marker specific for activated glycoprotein IIb/IIIa), 
platelets, endothelial microparticles, and soluble 
adhesion markers diminished with losartan in 
hypertensive patients with diabetes. They concluded 
that losartan together with simvastatin might prevent 
the development of cardiovascular events caused by 
platelets and microparticles in addition to reduction 
of blood pressure or lipid levels in hypertensive and 
hyperlipidemic patients with diabetes. On the contrary, 
Akdemir et al., (20) in their study investigating effects 
of losartan on platelet aggregation with ADP and 
ristocetin, found no significant differences. 
Yamada et al. (21) showed that spontaneous 
platelet aggregation was not significantly reduced 
after losartan treatment whilst CD62P was significantly 
decreased (p=0.016). These results suggested that 
losartan shows antiplatelet effect as measured by 
CD62P levels.
The LIFE study suggested that beneficial effect 
of losartan on stroke may result from a mosaic 
of mechanisms such as thrombus formation/
platelet aggregation rather than a single action 
(22). Losartan passivates ex vivo platelet activation, 
probably by means of blockade of TXA2 receptor-
dependent signaling (23). It has been shown that 
losartan significantly reduced megakaryocyte ploidy, 
megakaryocyte size, and lengthened cutaneous 
bleeding time, in hypertensive patients (4,24). 
Losartan reduced platelet aggregation via a TXA2-
dependent mechanism. The detractive effect of 
losartan on TXA2-dependent platelet activation was 
independent from its effect on angiotensin II (25). 
Glycoprotein VI (GPVI) is an important receptor of 
collagen-induced platelet activation (26). Ono et al. 
(26) reported that losartan (DuP-753) inhibits platelet 
aggregation and adhesion by means of GPVI. EXP3179 
is an active metabolite of losartan. EXP3179 functions 
as a specific inhibitor of GPVI independent of AT1-
receptor antagonism (27).
An in-vitro analysis has shown that losartan 
plus candesartan, compared to valsartan, resulted 
in a higher reduction in TXA2-analogue binding of 
platelets (28).
ARBs, including valsartan, irbesartan, olmesartan, 
and telmisartan significantly reduce serum levels 
of CRP. This effect is contradictory for losartan and 
candesartan (29). In our study, we did not observe 
changes in ESR and CRP values following treatment 
with losartan.
An intact and activated renin-angiotensin system 
(RAS) may be an important factor for erythropoiesis. 
Antihypertensive drug usage may be associated with 
a reduction in hemoglobin level. The mechanism 
of antihypertensive drug-related reduction in 
hemoglobin level include hemodilution, hemolytic 
anemia, and suppression of red blood cell production, 
as this occurs most commonly with angiotensin-
converting enzyme inhibitors and ARBs. Indeed, 
a dose-dependent decrease in hematocrit level is 
observed in the first months of such therapy (30,31).
In the current study, this hematological impression 
could be an additional benefit to antihypertensive 
effect via decreasing atherosclerotic process due to 
attenuated viscosity and inhibited platelet aggregation. 
The reduction in hemoglobin and hematocrit levels 
could be related to decrease in erythropoiesis via 
Ünübol et al. The Effect of Losartan on Platelet Aggregation
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direct or indirect (with the antihypertensive effect) 
inhibition of erythropoietin. The hematological effects 
along with antihypertensive effect of losartan could 
be important. This situation does not seem to be a 
group effect. 
Conclusion
Losartan may produce independent activities 
apart from its antihypertensive effects by providing 
significant reductions in platelet aggregation with 
ristocetin, hemoglobin and hematocrit levels. Thus it 
may be beneficial in the prevention of atherosclerosis 
and thrombosis. 
Study Limitations
There are some limitations in this study. First, 
platelet aggregometry can evaluate platelet activity 
in hypertensive patients, but has some limitations. 
Standardization of this process is difficult (32). 
Repeatability of this process is important to avoid 
incorrect results (33). However, these tests were not 
repeated in our study. Second, the sample size in our 
study was relatively small. Third, we were not able 
to evaluate the effects separately in stage 1 and 2 
hypertensive patients due to the limited number of 
subjects. 
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